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Abstract 
Intraoperative imaging with antibodies labeled with both a radionuclide for initial guidance and a 
near-infrared dye for adequate tumor delineation may overcome the main limitation of fluorescence 
imaging: the limited penetration depth of light in biological tissue. In this study, we demonstrate the 
feasibility and safety of intraoperative dual-modality imaging with the carbonic anhydrase IX (CAIX)- 
targeting antibody 111In-DOTA-girentuximab-IRDye800CW in clear cell renal cell carcinoma 
(ccRCC) patients.  
Methods: A phase I protein dose escalation study was performed in patients with a primary renal 
mass who were scheduled for surgery. 111In-DOTA-girentuximab-IRDye800CW (5, 10, 30, or 50 
mg, n=3 ccRCC patients per dose level) was administered intravenously and after 4 days SPECT/CT 
imaging was performed. Seven days after antibody injection, surgery was performed with the use of 
a gamma probe and near-infrared fluorescence camera.  
Results: In total, fifteen patients were included (12 ccRCC, 3 CAIX-negative tumors). No 
study-related serious adverse events were observed. All ccRCC were visualized by SPECT/CT and 
localized by intraoperative gamma probe detection (mean tumor-to-normal kidney (T:N) ratio 2.5 ± 
0.8), while the T:N ratio was 1.0 ± 0.1 in CAIX-negative tumors. ccRCC were hyperfluorescent at 
all protein doses and fluorescence imaging could be used for intraoperative tumor delineation, 
assessment of the surgical cavity and detection of (positive) surgical margins. The radiosignal was 
crucial for tumor localization in case of overlying fat tissue.  
Conclusion: This first in man study shows that tumor-targeted dual-modality imaging using 
111In-DOTA-girentuximab-IRDye800CW is safe and can be used for intraoperative guidance of 
ccRCC resection. 
Key words: carbonic anhydrase IX, clear cell renal cell carcinoma, intraoperative dual-modality imaging, 
fluorescence imaging, image-guided surgery  
Introduction 
Intraoperative fluorescence imaging has proven 
to be valuable in cancer surgery to enhance tumor 
visualization in challenging situations such as 
multifocal disease [1] or organ-sparing surgery [2]. It 
can be used to differentiate tumor from normal tissue. 
By conjugating a fluorescent dye to a monoclonal 
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antibody against a tumor-specific antigen, a tumor- 
targeting fluorescent tracer can be created. Several 
studies have already shown the feasibility of this 
tumor-targeted approach for intraoperative fluoresce-
ence imaging [3-5]. However, the major pitfall of 
fluorescence imaging is the limited penetration depth 
of light in tissue, restricting detection to superficial 
tumors. This inherent problem can be overcome by 
combining fluorescence imaging with radiodetection, 
as gamma radiation has a high penetration depth in 
tissue. By dual-labeling monoclonal antibodies with a 
radionuclide for initial guidance and a near-infrared 
dye for real-time tumor delineation, the advantages of 
radiodetection and fluorescence imaging are 
combined. Due to specific accumulation of the 
antibody in tumor tissue, tumor-targeted dual- 
modality imaging may guide the surgeon to perform 
a complete tumor resection. We now describe the first 
in man study using this tumor-targeted dual-modality 
imaging technique during surgery.  
Approximately 115,000 patients are diagnosed 
with renal cell carcinoma (RCC) in Europe every year 
[6]. A large proportion of these patients is treated by 
nephron-sparing surgery (NSS) with a trend towards 
NSS of larger or more complex tumors [7, 8]. Positive 
surgical margins (PSM) after NSS are seen in up to 7% 
of patients, but percentages up to 15% are reported in 
NSS for imperative indications (e.g., solitary kidney) 
[9]. Improved intraoperative tumor visualization by 
dual-modality imaging may help to perform 
oncologically safe NSS. Girentuximab is a monoclonal 
antibody that recognizes carbonic anhydrase IX 
(CAIX) that has been used extensively to target clear 
cell RCC (ccRCC), since more than 95% of ccRCC 
express CAIX [10-13]. Preclinical studies with 
dual-labeled girentuximab have shown the feasibility 
of tumor-targeted dual-modality imaging [14-17]. 
Thus, this technique may be useful during surgery to 
localize, visualize and delineate ccRCC. Furthermore, 
it may be used to detect residual tumor tissue or PSM 
and thereby improve the outcome of surgery.  
The aim of this clinical trial was to evaluate the 
safety of 111In-DOTA-girentuximab-IRDye800CW and 
to demonstrate the feasibility of preoperative as well 
as intraoperative detection of ccRCC with this 
CAIX-targeted dual-modality imaging agent. 
Materials and Methods 
Study design 
This was a single center phase I protein dose 
escalation study in adult patients with a primary renal 
mass who were scheduled for partial or radical 
nephrectomy. The focus of the trial design was to 
collect safety data and to collect data that support the 
intended clinical use and indication statement [18]. 
Written informed consent was obtained from all 
patients. Patients with a known non-ccRCC subtype 
were excluded. Because preclinical data in primates 
suggested that another antibody-IRDye800CW 
conjugate influenced corrected QT (QTc) intervals, a 
measurement for electrical depolarization and 
repolarization of the hearts’ ventricles [19], patients 
with a pre-existent prolonged QTc interval were 
excluded. 111In-DOTA-girentuximab-IRDye800CW (5, 
10, 30, or 50 mg, n=3 ccRCC patients per dose level) 
was administered intravenously and after 4 days 
SPECT/CT imaging was performed. Seven days after 
antibody injection, surgery was performed with the 
use of a gamma probe and near-infrared fluorescence 
camera. The aim of this study was to demonstrate the 
safety and feasibility of intraoperative dual-modality 
imaging with the carbonic anhydrase IX (CAIX)- 
targeting antibody 111In-DOTA-girentuximab-IRDye 
800CW in clear cell renal cell carcinoma (ccRCC) 
patients. Safety was scored by the number of adverse 
events (AE) according to the common terminology 
criteria for adverse events version 4.0 (CTCAE v4.0). 
Feasibility was defined as the ability to detect a 
discriminatory fluorescence and/or radioactive signal 
in ccRCC tumor tissue compared to normal kidney 
tissue. Patients with a CAIX-negative tumor on final 
histology were only included in the safety analysis. 
The study was approved by the regional Medical 
Ethics Committee of the region Arnhem-Nijmegen 
and was registered on clinicaltrials.gov (NCT: 
02497599). A study flowchart of the design of the 
study is shown in Fig. S1. 
Preparation of 
111In-DOTA-girentuximab-IRDye800CW 
DOTA-girentuximab-IRDye800CW was produ-
ced under metal free conditions and protected from 
light and production complied with Good 
Manufacturing Practice quality. Chimeric girentuxi-
mab 5 mg/mL (Wilex AG, Munich, Germany) was 
incubated with a 2−2.5-fold molar excess (preferred 
conjugation ratio 0.5-2.0) of IRDye800CW-NHS ester 
(LI-COR biosciences, Lincoln, NE, USA) and next with 
a 25-fold molar excess (preferred conjugation ratio of 
0.5-3.0) of the chelator DOTA-NHS ester (Macro-
cyclics, Dallas, TX, USA) in a 1.25 M NaHCO3 buffer 
pH 8.5. Excess IRDye800CW-NHS ester and 
DOTA-NHS ester were removed by dialysis against 
0.25 M ammoniumacetate pH 5.5 for 3 days. The 
integrity of the dual-labeled antibody conjugate was 
checked before i.v. administration. Radiochemical 
purity after radiolabeling was determined by high- 
performance liquid chromatography analysis. The 
integrity of the antibody-dye conjugate was checked 
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by measuring the amount of free IRDye800CW in the 
preparation by high-performance liquid chromate-
graphy. To confirm the tumor-specific binding of the 
dual-labeled antibody, the immunoreactive fraction of 
111In-DOTA-girentuximab-IRDye800CW was determ-
ined as described by Lindmo [20] and exceeded 70%. 
DOTA-girentuximab-IRDye800CW was stored in the 
dark at 4 °C until use. 
 Radiolabeling was performed by incubating 
DOTA-girentuximab-IRDye800CW during 30 min at 
45 °C with 100-120 MBq of Indium-111 (Mallinckrodt 
Pharmaceuticals, ‘s Hertogenbosch, The Netherlands). 
Unlabeled DOTA-girentuximab-IRDye800CW was 
added to obtain the required protein dose. Radio-
chemical purity was determined by high-performance 
liquid chromatography. 100 MBq of the final product 
was diluted in NaCl 0.9% to a final volume of 10 mL 
and pulled up in a syringe shortly before injection. 
Two patients received only 75 MBq instead of 100 
MBq due to technical problems. Standards of the 
injected dose (ID) were prepared in triplicate to be 
able to quantify antibody accumulation in surgically 
obtained tissue samples. 
Dual-labeled girentuximab injection 
Seven days before surgery, patients were 
injected intravenously with 111In-DOTA-girentuxi-
mab-IRDye800CW (100 MBq). Previous studies with 
radiolabeled girentuximab have shown an optimal 
protein dose of 5-10 mg [10, 12]. Since this was the 
first clinical trial with 111In-DOTA-girentuximab- 
IRDye800CW and conjugation of IRDye800CW 
slightly changes the biodistribution of girentuximab 
[15], the dose escalation study was repeated. The 
rationale for the dose escalation schema was to 
determine the dose with the highest tumor-to-normal 
tissue ratio and the best intraoperative signal for both 
imaging modalities. Protein doses of 5, 10, 30 or 50 mg 
were chosen in the current study. At each protein 
dose level three patients were included. When final 
histology revealed a CAIX-negative tumor, the patient 
was replaced by a subsequent patient at that dose 
level. Patients were monitored for AE for three hours 
and ECG-monitoring with measurement of the QTc 
interval was performed before and after injection. 
Blood samples were taken for pharmacokinetic and 
safety analyses.  
SPECT/CT imaging 
Four days after injection whole body anterior 
and posterior gamma camera images and SPECT/CT 
imaging of the abdomen were performed with a 
dual-head Symbia T16 Truepoint SPECT/CT scanner 
(Siemens Healthcare, The Hague, The Netherlands). 
After acquisition of a low dose, non-contrast enhan-
ced CT, scintigraphic imaging was performed 
clockwise continuously from 0-180°, with 64 views, 19 
s per view with medium energy all-purpose parallel- 
hole collimators. Accumulation of 111In-DOTA-girent-
uximab-IRDye800CW in tumors was scored as absent 
or present by an experienced nuclear medicine 
physician (WO).  
Dual-modality image-guided surgery 
Standard of care surgery was performed, 
supplemented with gamma probe detection and 
near-infrared fluorescence imaging (NIRF) to assess 
accumulation of 111In-DOTA-girentuximab-IRDye800-
CW in the tumor. Intraoperative scintillation counting 
was performed with the SOE 311-AL laparoscopic 
gamma probe with a lateral window (diameter 10 
mm, length 38.7 cm) or the Europrobe 1 for open 
surgery (Eurorad, Strasbourg, France). An 
intraoperative tumor-to-normal kidney tissue ratio 
(T:N) was calculated by dividing the maximum 
counts per second (cps) in tumor by the maximum cps 
in adjacent ipsilateral normal kidney tissue. NIRF was 
performed with the Karl Storz NIR/ICG System (Karl 
Storz GmbH & co, Tuttlingen, Germany) for 
laparoscopic surgery, or the QMI Spectrum NIR 
fluorescence camera for both laparoscopic and open 
surgery (Quest Medical Imaging, Middenmeer, The 
Netherlands). In addition, ex vivo dual-modality 
imaging of the resected specimens was performed.  
Tissue analyses 
NIRF and autoradiography were performed on a 
tissue slice of the resected specimen as described 
previously [17]. In short, a 5-10 mm thick slice of the 
resected specimen containing tumor and normal 
kidney tissue was obtained from the pathology 
department. First, NIRF was done using the Odyssey 
flatbed fluorescence scanner (800 nm channel, focus 
1.0 mm) (LI-COR biosciences, Lincoln, NE). Next, 
autoradiography was performed by exposing a 
phosphor imaging plate for approximately one hour 
to the tissue slice. This plate was developed using the 
Typhoon FLA 7000 Phosphor Imager and analyzed 
with Aida Image Analyzer v. 4.21. To quantify tissue 
accumulation of 111In-DOTA-girentuximab-IRDye800-
CW, samples of tumor and normal kidney 
parenchyma from the tissue slice and samples of 
blood were taken, weighed and measured in a gamma 
counter (2480 WIZARD2, Perkin Elmer, Boston, MA) 
together with aliquots of the injected dose. Tracer 
accumulation was expressed as percentage of the 
injected dose per gram of tissue (%ID/g). Next, the 
5-10 mm thick tissue slice was fixed in formalin and 
embedded in paraffin. In case of partial nephrectomy 
specimens, the tissue slice was embedded in its 
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entirety to be able to compare signal distribution in 
the tissue slices with the tissue sections. Fluorescence 
imaging of the tissue sections was done using the 
Odyssey flatbed fluorescence scanner (800 nm 
channel, focus 1.0 mm). Finally, hematoxylin and 
eosin staining and M75-staining for CAIX-expression 
were performed on 4 µm formalin-fixed paraffin- 
embedded tissue sections and interpreted by a 
uropathologist. 
Statistics 
Statistical analyses were performed using IBM 
SPSS Statistics 22.0. One-way ANOVA testing with 
post-hoc Bonferroni correction was performed to test 
for significant differences between the different 
protein dose levels in T:N ratios. Independent sample 
t-tests were performed to compare mean T:N ratios 
and tracer accumulation (%ID/g) between ccRCC and 
CAIX-negative tumors and a paired t-test to compare 
tracer accumulation between tumor and normal 
kidney tissue. Values are expressed as mean with 
standard deviation (SD). An alpha of 0.05 was used in 
all analyses and p<0.05 was considered significant. 
The biological half life of 111In-DOTA-girentuxim-
ab-IRDye800CW was calculated using bi-exponential 
regression analysis in MATLAB version R2014b. 
Graphs were made using GraphPad Prism 5.03.  
Results  
Patient population 
Written informed consent was obtained from 17 
patients with a primary renal mass who were 
scheduled for partial or radical nephrectomy. Two of 
these patients were excluded before injection of 
111In-DOTA-girentuximab-IRDye800CW because of a 
prolonged QTc-interval. Three patients with a 
CAIX-negative tumor were replaced. An overview of 
patient characteristics is given in Table 1 and a study 
flowchart can be found in Fig. S1. 
Safety analysis 
All 15 patients were monitored for three hours 
after antibody injection and no infusion-related 
(serious) adverse events ((S)AE) nor any significant 
changes in vital signs were observed. ECG-analysis 
before and one hour after antibody injection showed 
no prolongation of the QTc interval. Blood samples 
that were taken for pharmacokinetic and safety 
analysis revealed no significant abnormalities in 
blood values after antibody injection. Five possibly 
related grade 1 AE were observed, while all other AE 
were related to surgery (Table S1).  
Preoperative SPECT/CT imaging 
All CAIX-expressing tumors were visualized 
preoperatively by SPECT/CT, while no uptake was 
seen in CAIX-negative tumors (patients #13-15). Some 
physiological liver uptake was observed. False 
positive accumulation of 111In-DOTA-girentuximab- 
IRDye800CW was observed by SPECT/CT in a 
CAIX-negative adrenal adenoma and a cyst in the 
contralateral kidney in patient #12. In patient #6, 
accumulation of 111In-DOTA-girentuximab-IRDye-
800CW was visualized by the SPECT in a known bone 
metastasis (first lumbar vertebra). Unfortunately, this 
lesion was not accessible for intraoperative imaging 
during surgery (not in the surgical field). The other 
patients did not have metastatic disease. 
Intraoperative dual-modality imaging 
During surgery, all 12 ccRCC could be localized 
by gamma probe measurements with a mean (T:N) 
ratio of 2.5 ± 0.8 (Fig. 1 and Movie S1), while the T:N 
ratio in the 3 CAIX-negative tumors was significantly 
lower (1.0 ± 0.1, p<0.05). The highest T:N ratio (3.3 ± 
0.6) was observed in the 10 mg dose group. T:N ratios 
did not differ significantly between the various 
protein doses (p=0.22). Radioactive probe guidance 
proved to be essential for intraoperative tumor 
localization, especially when fat covered the tissue of 
interest, since the fluorescence signal was significantly 
attenuated by the perinephric fat. 
After tumor localization and exposure of the 
tumor, NIRF was used for real-time tumor 
visualization and differentiation of tumor from 
normal kidney tissue (Fig. 2, Fig. 3 and Movie S2). 
Hyperfluorescence of tumors was observed during 
surgery and/or on the bench in all ccRCC at all 
protein dose levels. Fluorescence of normal kidney 
parenchyma was low (Fig. 2). Fluorescence imaging 
during open surgery was straightforward, but for 
laparoscopic surgery a perpendicular approach of the 
tumor with the fluorescence camera proved to be 
essential for accurate NIRF imaging. This was a 
complicating factor in laparoscopic surgery, especially 
in posterior tumors. Iso- or hypofluorescence was 
observered in two out of three CAIX-negative tumors 
(patients #14 and #15), while hyperfluorescence was 
observed in one CAIX-negative pseudocystic lesion 
(patient #13), but since no radioactive signal was 
detectable, it was considered to be autofluorescence of 
the cyst content. 
One PSM was correctly identified by ex vivo 
NIRF of the resected specimens (patient #11). 
Additionally, resected tissue contained vital tumor, as 
confirmed by histopathology (Fig. 3). In all other 
ccRCC, a rim of hypofluorescent, normal kidney 
parenchyma was visible around the tumor and final 
histology confirmed negative surgical margins. 
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Table 1. Patients characteristics. 
No. # Dose (mg) Age Sex Tumor size (cm) Surgery T-stage Pathological margin Histology CAIX 
1 5 67 F 6.0 RALN pT1b R0 ccRCC + 
2 5 71 F 3.6 RALPN pT1a R0 ccRCC + 
3 5 76 F 8.0 LN pT1b R0 ccRCC + 
4 10 59 M 3.3 RALPN pT1a R0 ccRCC + 
5 10 75 M 5.0 LN pT1b R0 ccRCC + 
6 10 76 M 6.0 LN pT1b (M1) R0 ccRCC + 
7 30 69 M 2.5 RALPN pT1a R0 Papillary ccRCC + 
8# 30 76 M 2.5 RALPN pT1a R0 ccRCC + 
9 30 55 F 2.8 OPN pT1a R0 ccRCC + 
10 50 58 M 5.7 RALPN pT1b R0 ccRCC + 
11 50 57 F 5.4 OPN pT3a R1* ccRCC + 
12 50 65 M 3.7 RALPN pT1a R0 ccRCC + 
13 30 64 M 1.5 RALPN - R0 Pseudocyst - 
14 50 63 M 3.2 & 1.8  RALPN - R1 Angiomyolipomas - 
15 50 76 V 2.5 RALPN pT1a R0 Clear cell papillary RCC - 
LN: laparoscopic nephrectomy; OPN: open partial nephrectomy; RAL(P)N: robot-assisted laparoscopic (partial) nephrectomy.  
#Due to logistical reasons, surgery in patient 8 was performed 6 days after injection (instead of 7).  
*Tumor tissue was present in the deep surgical margin of the primary resected specimen and further resection contained vital tumor tissue. Since the tumor was not resected 
en bloc, unequivocal assessment of the surgical margin was not possible. 
 
Tissue analyses  
A high T:N fluorescence contrast was seen in all 
ccRCC by fluorescence imaging of the 5-10 mm slices 
of the resected specimens (Fig. S2). Considerable 
intratumoral heterogeneity in the uptake of 111In- 
DOTA-girentuximab-IRDye800CW was observed 
macroscopically, with high uptake at the tumor 
borders and lower uptake in the tumor center, most 
likely due to perfusion differences limiting tumoral 
penetration of girentuximab. Histopathology of the 
tissue section showed homogeneous expression of 
CAIX in tumors coinciding with the distribution of 
the fluorescence signal (Fig. 4). 
Maximum tumor uptake of 111In-DOTA-giren-
tuximab-IRDye800CW in ccRCC as measured with a 
gamma counter ranged from 0.04–0.58 %ID/g, while 
uptake was significantly lower in normal kidney 
tissue (mean 0.004±0.002 %ID/g, p<0.05). In CAIX- 
negative tumors, 0.01±0.01 %ID/g 111In-DOTA-giren-
tuximab-IRDye800CW was detected, possibly related 
to the enhanced permeability and retention effect. 
Pharmacokinetic analyses 
The average blood levels of 111In-DOTA- 
girentuximab-IRDye800CW were 0.024±0.009, 0.019± 
0.007, 0.007±0.003 and 0.004±0.002 %ID/g at 5 min, 3 
h, 4 d and 7 d post injection, respectively. When fitting 
the curves in a two-compartment model, the half life 
in the distribution phase was 1.4±1.7 h (t1/2α) and in 
the clearance phase 73.5±17.0 h (t1/2β) (Fig. 5). 
Discussion  
This study describes the first clinical application 
of tumor-targeted dual-modality imaging with a 
dual-labeled monoclonal antibody. It shows that this 
novel technique is safe and allows successful 
intraoperative visualization of 
tumors in patients with ccRCC. 
Combining a radiolabel for preop-
erative imaging and intraoperative 
probe-guided tumor localization 
and a fluorescent label for tumor 
delineation proved to be a 
powerful synergy. CcRCC could 
be localized intraoperatively by 
gamma probe detection, and after 
surgical exposure of the tumor, 
NIRF could be used to delineate 
tumors and detect PSM. This 
potential of targeted dual-modal-
ity imaging can also be exploited 
in many other cancer types, by 
replacing girentuximab by another 
tumor-targeting antibody.  
 
 
 
Figure 1. Intraoperative gamma probe measurements (T:N ratios). Each dot represents one patient and the 
horizontal line represents the mean per dose level. The highest T:N ratios were observed after administration 
of 10 mg 111In-DOTA-girentuximab-IRDye800CW, but differences between the dose levels were not 
statistically significant. The T:N ratio in the CAIX-negative tumors was significantly lower than in the 
CAIX-positive tumors (p<0.05). 
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Figure 2. Intraoperative NIRF to guide complete tumor resection (patient #9). (A) Intraoperative NIRF before tumor resection: Hyperfluorescence of a ccRCC was 
seen after injection of 111In-DOTA-girentuximab-IRDye800CW. NIRF was successfully used for tumor border delineation. (B) Ex vivo NIRF of the resected specimen 
showed a rim of normal hypofluorescent tissue around the hyperfluorescent tumor indicating a negative surgical margin, as confirmed by histopathology. (C) 
Intraoperative NIRF of the surgical cavity after tumor resection indicated complete tumor removal. 
 
 
Figure 3. Dual-modality imaging after injection of 111In-DOTA-girentuximab-IRDye800CW (patient #11). (A) Preoperative SPECT/CT imaging confirmed the 
presence of a CAIX-expressing ccRCC and revealed that this tumor extended deep into this patients’ monokidney. (B) Intraoperative NIRF showed 
hyperfluorescence of the tumor. (C) Assessment of the resected tumor specimen with NIRF suggested tumor in the surgical margin (square), which was subsequently 
confirmed by histopathology. (D) NIRF demonstrated that further resection contained vital tumor, again confirmed by histopathology. (E) NIRF was used to assess 
the presence of tumor (square) in additional resected tissue fragments. Histopathology confirmed that the fragment consisted mainly of fibrotic tissue, but also a 
tumor fragment of 2 mm. Scale bars are an approximation. 
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Figure 4. Tissue processing and tissue section analysis (patient #8). Thin (5-10 mm) tissue slices (A) of the resected specimens were analyzed by autoradiography 
(B) and near-infrared fluorescence imaging (C). Both the radioactive and fluorescence signals were localized in tumor tissue. Histopathology of a tissue section 
showed homogeneous expression of CAIX in tumors coinciding with the distribution of the fluorescence signal. (D) H&E staining with the tumor annotated. (E) 
M75-staining showed a high and homogenous expression of CAIX in the tumor, visually overlapping with the distribution of the fluorescence signal. (F) Fluorescence 
imaging of a tissue section showed that T:N contrast is high at the tumor borders. 
 
 
 
Figure 5. Blood clearance of dual-labeled girentuximab over seven days after 
injection (p.i.) fitted to a two-compartment model. Inset: clearance during the 
first three hours is depicted in more detail. Values are expressed as mean ± SD 
of 14 patients, since pharmacokinetic data of patient #3 were incomplete. 
 
Administration of 111In-DOTA-girentuximab- 
IRDye800CW was well tolerated, as expected based 
on previous extensive experience with radiolabeled 
girentuximab [11, 12, 21, 22]. No prolongation of the 
QTc-interval was found and no study drug-related 
SAE were observed. In two patients (13%) hospital 
admission was prolonged due to complications of 
surgery (CTCAE grade III), which is in accordance 
with complication rates reported in the literature [23]. 
Thus, intraoperative dual-modality imaging with 
111In-DOTA-girentuximab-IRDye800CW is a safe 
procedure.  
Considering the trend to treat larger and more 
complex tumors by NSS [8, 24, 25], there is an 
increasing need for tools to achieve complete tumor 
resection, while supporting oncologically safe NSS. 
The advantage of using NIR dyes over visible light 
dyes is that there is less autofluorescence, less 
scattering and a slightly higher tissue penetration 
depth [26]. Furthermore, since the dye is not visible by 
the human eye, the dye does not change the 
appearance of the surgical field, in contrast to, for 
example, blue dye. This implies that a light source and 
a camera system with special filters are needed, which 
can be argued as a disadvantage. NIRF after injection 
of indocyanine green has been used to delineate renal 
tumors. Indocyanine green accumulates in normal 
kidney parenchyma, resulting in relative hypofluore-
scence of RCC [27-29]. Disadvantages of this approach 
are that it is non-specific and hypofluorescent fat 
tissue can be misinterpreted as residual tumor tissue 
[27]. By targeting tumor-associated antigens, a 
positive T:N contrast can be obtained. Folate-receptor 
alpha-targeted NIRF has shown promise to detect 
superficial tumor lesions in ovarian cancer [1] and has 
also been explored in RCC, but conflicting results 
were reported [30, 31]. 
Because of the high expression of CAIX on more 
than 95% of primary ccRCC, CAIX is a more 
promising target for targeted imaging of ccRCC. The 
current study shows that CAIX-targeted dual- 
modality imaging could sensitively detect and 
delineate ccRCC during surgery. NIRF has the 
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additional advantage to assess the surgical margins ex 
vivo as well as the surgical cavity in vivo. The 
radiosignal allowed both preoperative evaluation of 
tumor extension with SPECT/CT and intraoperative 
tumor localization by gamma probe detection. The 
latter proved to be essential when perinephric fat 
covered the tumor and in largely endophytic tumors. 
An additional advantage of the radiolabel is that it 
allows accurate quantification (T:N ratio or %ID/g) of 
tracer accumulation, which is important as 
quantification of a fluorescence signal may be 
complicated due to scattering and attenuation of light 
in biological tissue. The main advantage of the 
dual-labeled approach over co-injection of two 
separate antibodies is that both signals originate from 
the same molecule. This may be important, as 
conjugating the antibody with fluorescent dyes may 
alter the in vivo behavior of the conjugate [15]. 
Previous analyses showed that radiolabeled 
girentuximab remained intact and could be visualized 
on tumor cells ex vivo [32-34]. Based on the ratios 
used, approximately 74% of the girentuximab 
molecules are truly dual-labeled (containing at least 
one DOTA and one IRDye800CW molecule) [15]. 
Thus, we assume that the quantification of the 
radiolabel is representative for targeting of the intact 
antibody. Indeed, we observed a perfect visual 
overlap between the fluorescence and radioactive 
image in ex vivo analysis (Fig. 4), substantiating that 
the antibody remained intact in the tumor. The very 
low accumulation of 111In-DOTA-girentuximab- 
IRDye800CW in CAIX-negative tumors is adding to 
the evidence that uptake is primarily mediated by 
CAIX expression and only slightly by the enhanced 
permeability and retention effect. Therefore, 
preoperative 111In-DOTA-girentuximab-IRDye800CW 
SPECT/CT imaging also has great diagnostic value 
since it allows for noninvasive confirmation that the 
tumor is a CAIX-expressing ccRCC. PET and SPECT 
studies with Iodine-124 labeled and Indium-111 
labeled girentuximab, respectively, have shown the 
feasibility of this approach [11, 12, 21]. Distinction of 
ccRCC from other renal lesions can be difficult, since 
studies have shown that in up to 25% of patients that 
undergo surgery for small renal masses, final 
histology shows benign disease [35]. 
Despite the heterogeneous uptake of 111In- 
DOTA-girentuximab-IRDye800CW in the tumor, a 
high T:N fluorescence contrast was observed at the 
tumor margins, which is essential for detection of 
tumor remnants and to subsequently guide additional 
resection of tumorous tissue. Van Driel et al. have 
shown that a minimum of 1 mm3 tumor tissue could 
be detected with the NIRF system that was used in the 
current study [36]. Recently, we have shown in an 
animal model that submillimeter micrometastases 
could be detected with dual-modality imaging with 
dual-labeled antibodies [37]. However, the detection 
of small lesions is dependent on several factors, such 
as tumor vascularization, antigen expression, 
background tissue signal and tumor location. The 
highest T:N gamma probe ratio (3.3±0.64) was found 
at the 10 mg dose level and a trend towards a lower 
T:N contrast at higher protein doses was seen. 
Although the highest absolute amount (in theory the 
highest signal intensity) of protein per gram of tumor 
tissue (% ID/g × protein dose) was found at the 30 mg 
dose level, this resulted in a slightly decreased T:N 
contrast (gamma probe). This is in accordance with 
results of the studies with 131I-girentuximab and may 
be attributed to antigen saturation at higher protein 
doses [10, 38]. Therefore, a protein dose of 10 mg was 
considered to be the optimal dose when taking into 
account both imaging modalities. 
Addition of fluorescent molecules to a 
radiolabeled antibody may affect its biodistribution 
and tumor-specific accumulation. Animal studies 
have shown that the addition of up to two fluorescent 
molecules per girentuximab molecule (substitution 
ratio) only slightly effects its biodistribution and 
specific tumor accumulation [15]. Since the 
substitution ratio in the current study was between 1.0 
and 2.0, no decrease in specific tumor accumulation 
was expected and indeed tumor uptake was 
comparable to radiolabeled girentuximab [22]. In 
addition, pharmacokinetic analyses confirmed that 
blood clearance of 111In-DOTA-girentuximab-IRDye-
800CW is similar to that of 111Indium-DTPA- 
girentuximab (t1/2β 73.5±17.0 h versus t1/2 α+β 58±18 
h) [39]. The required interval between tracer injection 
and tumor targeting of approximately 7 days implies 
that the surgeon should decide well before surgery if 
intraoperative imaging will be needed. Pharmac-
okinetics are faster with smaller molecules, but small 
molecules may have the disadvantage of high 
physiological renal clearance, thereby obscuring 
ccRCC tumors [40]. Besides low normal kidney 
uptake, a further advantage of IgG molecules over 
antibody fragments and small molecules is the 
convenient chemistry of radiolabeling and 
fluorescence labeling, without significantly compr-
omising the immunoreactivity or altering the 
pharmacokinetics [15]. Previous studies with 
radiolabeled girentuximab have shown that high 
tumor-to-normal tissue ratios were obtained 4 to 7 
days after injection [12, 41]. In the current study, we 
aimed to show the feasibility of dual-modality 
imaging and we preferred to perform both SPECT and 
fluorescence imaging between 4 to 7 days after 
injection. The choice to perform SPECT/CT imaging 4 
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days after injection and fluorescence imaging 7 days 
after injection was mainly based on logistical reasons. 
Future studies may focus on optimizing this time 
interval for dual-labeled girentuximab.  
In the current study, dual-modality imaging 
devices were not integrated in the standard set of 
surgical instruments and therefore switching between 
standard surgery and dual-modality image-guided 
surgery took additional time. After introducing the 
standard surgical instruments and opening the 
retroperitoneum, the laparoscopic gamma probe was 
used to localize the tumor. After exposure of the 
tumor, the fluorescence camera was introduced. 
Subsequently, surgery was continued with the 
standard surgical instruments. Therefore, dual- 
modality imaging could only be performed before 
resection and after terminating the critical period of 
kidney ischemia and haemostasis, making deep 
surgical margins less accessible for NIRF. Integration 
of imaging devices into the standard surgical 
instruments would increase the convenient use of 
dual-modality imaging. Except for its use during NSS, 
the specific accumulation of 111In-DOTA-giren-
tuximab-IRDye800CW in ccRCC implies that 
dual-modality imaging may also be advantageous for 
lymph node dissection or metastasectomy. Since this 
was a phase I first in man study with the objective to 
assess the safety and feasibility, the surgical strategy 
(radical or partial nephrectomy) could not be changed 
based on intraoperative imaging results alone. 
Whether targeted dual-modality imaging using 
111In-DOTA-girentuximab-IRDye800CW reduces PSM 
or ccRCC recurrences needs to be studied in 
subsequent prospective studies. 
Abbreviations 
CAIX: carbonic anhydrase IX; ccRCC: clear cell 
renal cell carcinoma; T:N ratio: tumor-to-normal 
kidney ratio; PSM: positive surgical margin; NSS: 
nephron-sparing surgery; QTc interval: corrected QT 
interval; (S)AE: (serious) adverse event; CTCAE: 
common terminology criteria for adverse events; ID: 
injected dose; %ID/g: percentage of the injected dose 
per gram; NIRF: near-infrared fluorescence imaging; 
cps: counts per second; LN: laparoscopic nephre-
ctomy; OPN: open partial nephrectomy; RAL(P)N: 
robot-assisted laparoscopic (partial) nephrectomy.  
Acknowledgments 
The authors thank D. Lobeek for her help with 
the pharmacokinetic analysis and D.L. Bos and M. de 
Weijert for their technical assistance. 
Supplementary Material  
Supplementary figures and tables. 
http://www.thno.org/v08p2161s1.pdf  
Movie S1. http://www.thno.org/v08p2161s2.mp4  
Movie S2. http://www.thno.org/v08p2161s3.mp4  
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et 
al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by 
folate receptor-alpha targeting: first in-human results. Nat Med. 2011; 17: 
1315-9. 
2. Okusanya OT, DeJesus EM, Jiang JX, Judy RP, Venegas OG, Deshpande CG, et 
al. Intraoperative molecular imaging can identify lung adenocarcinomas 
during pulmonary resection. J Thorac Cardiovasc Surg. 2015; 150: 28-35 e1. 
3. Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, 
Brandwein-Gensler M, et al. Safety and Tumor Specificity of 
Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin 
Cancer Res. 2015; 21: 3658-66. 
4. Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, et al. 
Threshold Analysis and Biodistribution of Fluorescently Labeled 
Bevacizumab in Human Breast Cancer. Cancer Res. 2016; 77: 623-31. 
5. Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, et 
al. Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW 
Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility 
Study. Clin Cancer Res. 2017; 23: 2730-41. 
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, 
Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates 
for 40 countries in 2012. Eur J Cancer. 2013; 49: 1374-403. 
7. Meyer C, Hansen J, Becker A, Schmid M, Pradel L, Strini K, et al. The 
Adoption of Nephron-Sparing Surgery in Europe - A Trend Analysis in Two 
Referral Centers from Austria and Germany. Urol Int. 2016; 96: 330-6. 
8. Derweesh IH, Autorino R, Bensalah K, Capitanio U. Partial Nephrectomy for 
Large or Complex Masses: Option or Obsolete? Eur Urol. 2017; 72: 76-7. 
9. Marszalek M, Carini M, Chlosta P, Jeschke K, Kirkali Z, Knuchel R, et al. 
Positive surgical margins after nephron-sparing surgery. Eur Urol. 2012; 61: 
757-63. 
10. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, 
Koenders EB, et al. Targeting of renal cell carcinoma with iodine-131-labeled 
chimeric monoclonal antibody G250. J Clin Oncol. 1997; 15: 1529-37. 
11. Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron 
emission tomography/computed tomography identification of clear cell renal 
cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013; 31: 187-94. 
12. Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, 
Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic 
tool in clear cell renal cell carcinoma. Eur Urol. 2013; 63: 1101-6. 
13. Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, 
Langenhuijsen JF, et al. Phase 1 radioimmunotherapy study with lutetium 
177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in 
patients with advanced renal cell carcinoma. Eur Urol. 2013; 64: 478-85. 
14. Muselaers CH, Stillebroer AB, Rijpkema M, Franssen GM, Oosterwijk E, 
Mulders PF, et al. Optical Imaging of Renal Cell Carcinoma with 
Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. J Nucl 
Med. 2014; 55: 1035-40. 
15. Rijpkema M, Bos DL, Cornelissen AS, Franssen GM, Goldenberg DM, Oyen 
WJ, et al. Optimization of dual-labeled antibodies for targeted intraoperative 
imaging of tumors. Mol Imaging. 2015; 14: 15-25. 
16. Muselaers CH, Rijpkema M, Bos DL, Langenhuijsen JF, Oyen WJ, Mulders PF, 
et al. Radionuclide and fluorescence imaging of clear cell renal cell carcinoma 
using dual labeled anti-carbonic anhydrase IX antibody G250. J Urol. 2015; 
194: 532-8. 
17. Hekman MC, Boerman OC, de Weijert M, Bos DL, Oosterwijk E, 
Langenhuijsen JF, et al. Targeted Dual-Modality Imaging in Renal Cell 
Carcinoma: An Ex Vivo Kidney Perfusion Study. Clin Cancer Res. 2016; 22: 
4634-42. 
18. Tummers WS, Warram JM, Tipirneni KE, Fengler J, Jacobs P, Shankar L, et al. 
Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer 
Detection. Cancer Res. 2017; 77: 2197-206. 
19. Zinn KR, Korb M, Samuel S, Warram JM, Dion D, Killingsworth C, et al. 
IND-Directed Safety and Biodistribution Study of Intravenously Injected 
Cetuximab-IRDye800 in Cynomolgus Macaques. Mol Imaging Biol. 2015; 17: 
49-57. 
20. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the 
immunoreactive fraction of radiolabeled monoclonal antibodies by linear 
 Theranostics 2018, Vol. 8, Issue 8 
 
 
http://www.thno.org 
2170 
extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 
72: 77-89. 
21. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. 
Preoperative characterisation of clear-cell renal carcinoma using 
iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients 
with renal masses: a phase I trial. Lancet Oncol. 2007; 8: 304-10. 
22. Steffens MG, Oosterwijk E, Zegwaart-Hagemeier NE, van't Hof MA, 
Debruyne FM, Corstens FH, et al. Immunohistochemical analysis of 
intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal 
cell carcinomas. Br J Cancer. 1998; 78: 1208-13. 
23. Maurice MJ, Ramirez D, Kara O, Malkoc E, Nelson RJ, Fareed K, et al. Optimal 
outcome achievement in partial nephrectomy for T1 renal masses: A 
contemporary analysis of open and robotic cases. BJU Int. 2017; 120: 537-43. 
24. Pavan N, Derweesh IH, Mir CM, Novara G, Hampton LJ, Ferro M, et al. 
Outcomes of Laparoscopic and Robotic Partial Nephrectomy for Large (>4 
Cm) Kidney Tumors: Systematic Review and Meta-Analysis. Ann Surg Oncol. 
2017; 24: 2420-8. 
25. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial 
Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal 
Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur 
Urol. 2017; 71: 606-17. 
26. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem 
Biol. 2003; 7: 626-34. 
27. Mitsui Y, Shiina H, Arichi N, Hiraoka T, Inoue S, Sumura M, et al. Indocyanine 
green (ICG)-based fluorescence navigation system for discrimination of 
kidney cancer from normal parenchyma: application during partial 
nephrectomy. Int Urol Nephrol. 2012; 44: 753-9. 
28. Tobis S, Knopf JK, Silvers C, Messing E, Yao J, Rashid H, et al. Robot-assisted 
and laparoscopic partial nephrectomy with near infrared fluorescence 
imaging. J Endourol. 2012; 26: 797-802. 
29. Tobis S, Knopf JK, Silvers CR, Marshall J, Cardin A, Wood RW, et al. Near 
infrared fluorescence imaging after intravenous indocyanine green: initial 
clinical experience with open partial nephrectomy for renal cortical tumors. 
Urology. 2012; 79: 958-64. 
30. Shum CF, Bahler CD, Low PS, Ratliff TL, Kheyfets SV, Natarajan JP, et al. 
Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in 
Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three 
Cases. J Endourol Case Rep. 2016; 2: 189-97. 
31. Guzzo TJ, Jiang J, Keating J, DeJesus E, Judy R, Nie S, et al. Intraoperative 
Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma. J Urol. 
2016; 195: 748-55. 
32. Oosterwijk-Wakka JC, de Weijert MC, Franssen GM, Leenders WP, van der 
Laak JA, Boerman OC, et al. Successful combination of sunitinib and 
girentuximab in two renal cell carcinoma animal models: a rationale for 
combination treatment of patients with advanced RCC. Neoplasia. 2015; 17: 
215-24. 
33. Steffens MG, Kranenborg MH, Boerman OC, Zegwaart-Hagemeier NE, 
Debruyne FM, Corstens FH, et al. Tumor retention of 186Re-MAG3, 
111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with 
renal cell carcinoma xenografts. Cancer Biother Radiopharm. 1998; 13: 133-9. 
34. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, et al. 
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron 
emission tomography imaging and nonlinear immunokinetic modeling: in 
vivo carbonic anhydrase IX receptor binding and internalization in mouse 
xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 
2014; 41: 985-94. 
35. Schachter LR, Cookson MS, Chang SS, Smith JA, Jr., Dietrich MS, Jayaram G, et 
al. Second prize: frequency of benign renal cortical tumors and histologic 
subtypes based on size in a contemporary series: what to tell our patients. J 
Endourol. 2007; 21: 819-23. 
36. van Driel PB, van de Giessen M, Boonstra MC, Snoeks TJ, Keereweer S, 
Oliveira S, et al. Characterization and evaluation of the artemis camera for 
fluorescence-guided cancer surgery. Mol Imaging Biol. 2015; 17: 413-23. 
37. Hekman MCH, Rijpkema M, Bos DL, Oosterwijk E, Goldenberg DM, Mulders 
PFA, et al. Detection of Micrometastases Using SPECT/Fluorescence 
Dual-Modality Imaging in a CEA-Expressing Tumor Model. J Nucl Med. 2017; 
58: 706-10. 
38. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, 
Debruyne FM, Corstens FH, et al. Immunohistochemical analysis of tumor 
antigen saturation following injection of monoclonal antibody G250. 
Anticancer Res. 1999; 19: 1197-200. 
39. Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, 
et al. Targeting of metastatic renal cell carcinoma with the chimeric 
monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient 
comparison. Clin Cancer Res. 2003; 9: 3953S-60S. 
40. Turkbey B, Lindenberg ML, Adler S, Kurdziel KA, McKinney YL, Weaver J, et 
al. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II 
pilot study. Abdom Radiol (NY). 2016; 41: 109-18. 
41. Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, 
O'Donoghue JA, et al. Dosimetric analysis of 177Lu-cG250 
radioimmunotherapy in renal cell carcinoma patients: correlation with 
myelotoxicity and pretherapeutic absorbed dose predictions based on 
111In-cG250 imaging. J Nucl Med. 2012; 53: 82-9. 
 
